Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania

APMIS

Volumn 121, Issue 5, 2013, Pages 431-436

  Kupcinskas, Limas ^a   Rasmussen, Lone ^b   Jonaitis, Laimas ^a   Kiudelis, Gediminas ^a   Jørgensen, Marianne ^b   Urbonaviciene, Neringa ^a   Tamosiunas, Vytas ^c   Kupcinskas, Juozas ^a   Miciuleviciene, Jolanta ^a   Kadusevicius, Edmundas ^a   Berg, Douglas ^d   Andersen, Leif P ^b  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b University of Copenhagen   (Denmark)

^c VYTAUTAS MAGNUS UNIVERSITY   (Lithuania)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amoxicillin; Clarithromycin; Helicobacter pylori; Metronidazole; Susceptibility; Tetracycline

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; MACROLIDE; METRONIDAZOLE; TETRACYCLINE;

ADULT; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; EPSILOMETER TEST; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVOLUTION, MOLECULAR; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LITHUANIA; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; TETRACYCLINE;

EID: 84876976154     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12012     Document Type: Article

References (26)

1. Janulaityte-Gunther D, Kupcinskas L, Pavilonis A, Valuckas K, Percival Andersen K, Wadstrom T. Helicobacter pylori antibodies and gastric cancer: a gender-related difference. FEMS Immunol Med Microbiol 2005;44:191-5.
2. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008;103:510-4.
3. Kupcinskas L, Jonaitis L, Kiudelis G. A 1 year follow-up study of the consequences of Helicobacter pylori eradication in duodenal ulcer patients: unchanged frequency of erosive oesophagitis and decreased prevalence of non-erosive gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2004;16:369-74.
4. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
6. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002;8:388-96.
7. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2012. [Epub ahead of print].
8. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007;59:783-5.
9. Kalach N, Serhal L, Asmar E, Campeotto F, Bergeret M, Dehecq E, et al. Helicobacter pylori primary resistant strains over 11 years in French children. Diagn Microbiol Infect Dis 2007;59:217-22.
10. Vecsei A, Kipet A, Innerhofer A, Graf U, Binder C, Gizci H, et al. Time trends of Helicobacter pylori resistance to antibiotics in children living in Vienna. Austria. Helicobacter 2010;15:214-20.
11. Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 2008;60:409-15.
12. Boyanova L, Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, et al. Two-decade trends in primary Helicobacter pylori resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis 2010;67:319-26.
13. Dzierzanowska-Fangrat K, Rozynek E, Celinska-Cedro D, Jarosz M, Pawlowska J, Szadkowski A, et al. Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study. Int J Antimicrob Agents 2005;26:230-4.
14. Loivukene K, Maaroos HI, Kolk H, Kull I, Labotkin K, Mikelsaar M. Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. Clin Microbiol Infect 2002;8:598-603.
15. Storskrubb T, Aro P, Ronkainen J, Wreiber K, Nyhlin H, Bolling-Sternevald E, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter 2006;11:224-30.
16. Jeong JY, Mukhopadhyay AK, Akada JK, Dailidiene D, Hoffman PS, Berg DE. Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibility and resistance to metronidazole. J Bacteriol 2001;183:5155-62.
17. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol 2004;58:419-28.
18. Goossens H, Ferech M, Vander SR, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87.
19. Dailidiene D, Bertoli MT, Miciuleviciene J, Mukhopadhyay AK, Dailide G, Pascasio MA, et al. Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother 2002;46:3940-6.
20. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322.
21. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
22. Occhialini A, Urdaci M, Doucet-Populaire F, Bebear CM, Lamouliatte H, Megraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997;41:2724-8.
23. Sakalauskas R, Bagdonas A, Bojarskas J, Dumcius S, Kudzyte J, Malakauskas K, et al. Diagnosis and treatment of pneumonia in adults and children (consensus of Lituanian pulmonologists). Medicina 2003;39:307-25.
24. Coenen S, Ferech M, Malhotra-Kumar S, Hendrickx E, Suetens C, Goossens H. European surveillance of antimicrobial consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe. J Antimicrob Chemother 2006;58:418-22.
25. Romano M, Iovene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008;61:1112-5.
26. Wang G, Taylor DE. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 1998;42:1952-8.